Navigation Links
Global Genetic disorders Partnering 2010-2017: Deal trends, players and financials
Date:3/9/2017

NEW YORK, March 9, 2017 /PRNewswire/ -- Summary

Global Genetic disorders Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the genetic disorders partnering deals and agreements entered into by the worlds leading healthcare companies


Read the full report: http://www.reportlinker.com/p03021530-summary/view-report.html


Description
Global Genetic Disorders Partnering 2010 to 2017 provides the full collection of Genetic Disorders disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Genetic Disorders partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Genetic Disorders partnering agreement structure
Genetic Disorders partnering contract documents
Top Genetic Disorders deals by value
Most active Genetic Disorders dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genetic Disorders dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genetic Disorders dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genetic Disorders deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Genetic Disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genetic Disorders deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genetic Disorders partnering deals by specific Genetic Disorders target announced since 2010. The chapter is organized by specific Genetic Disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genetic Disorders partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genetic Disorders partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genetic Disorders technologies and products.

Report scope

Global Genetic Disorders Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Genetic Disorders trends and structure of deals entered into by leading companies worldwide.

Global Genetic Disorders Partnering 2010 to 2017 includes:

Trends in Genetic Disorders dealmaking in the biopharma industry since 2010
Analysis of Genetic Disorders deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Genetic Disorders deal contract documents
Comprehensive access to over 3500 Genetic Disorders deal records
The leading Genetic Disorders deals by value since 2010
Most active Genetic Disorders dealmakers since 2010

The report includes deals for the following indications: Cystic Fibrosis (CF), Down syndrome, Fragile X Syndrome, Hereditary angioedema, Huntington's disease, Rare genetic disorders, Neurofibromatosis, Sickle cell disease, plus other genetic indications.

In Global Genetic Disorders Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Genetic Disorders Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 400 genetic disorders deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Read the full report: http://www.reportlinker.com/p03021530-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-genetic-disorders-partnering-2010-2017-deal-trends-players-and-financials-300421637.html


'/>"/>
SOURCE Reportlinker
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
2. Guidepoint Global Launches Two Major Enhancements to its Client Research Portal
3. Global Regulatory Milestones for Invibio Biomaterial Solutions
4. DuPont Joins Israel’s Office of the Chief Scientist Global Enterprise R&D Cooperation Framework
5. Global Metabolomics (Biomarker Discovery/Metabolite Detection/Metabolite Profiling) - 2013 Market Report
6. Lucintel's Analysis of Global Catalysts Industry: Chemical and Automobile Industries Play Crucial Role in Growth
7. Global Biochips and Microarrays 2013 Market Report
8. Global Bio-implants Market 2012-2016 New Research Report Now Available at MarketResearchReports.biz
9. USP Global Fellowship Awards Program Call for Applications
10. Medical Gases and Equipment Market is Expected to Reach USD 9 Billion Globally in 2018: Transparency Market Research
11. Global Food Safety Testing Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017 After spending the past ... support with crowdsourced data collection, GeneFo now offers this platform to ... aligning and amplifying support, adherence, and data collection vis a vis ... foundations mark the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... ... August 15, 2017 , ... Any expert in stem cell ... these disciplines for more than half a century. Despite their essential roles in ... is widely known that molecular tags developed for this purpose also tag other, more ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... encrypted shopping cart. Now mobile responsive, the new website makes it easy to ... anywhere in between. Users can now find detailed product information, educational industry content ...
(Date:8/11/2017)... 11, 2017  Market researcher Kalorama Information ... article regarding the telemedicine market.  The telemedicine ... Information.  The article, "Heart and Asthma ...  used information from Kalorama Information,s Remote Patient ... Market  (Sleep, Diabetes, Vital Signs /EKG ...
Breaking Biology Technology:
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):